NCT01353911View on ClinicalTrials.gov

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

PHASE2CompletedINTERVENTIONAL
Enrollment

368

Participants

Timeline

Start Date

June 27, 2011

Primary Completion Date

January 20, 2013

Study Completion Date

March 10, 2015

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Grazoprevir

Orally once daily in AM. Blinded or open-label depending on treatment arm.

DRUG

Boceprevir

Four 200 mg capsules orally three times daily.

DRUG

Placebo for Grazoprevir

Orally once daily in AM.

DRUG

Placebo for Boceprevir

Four capsules orally three times daily.

DRUG

Peg-interferon alfa-2b

1.5 μg/kg/week subcutaneous injection.

DRUG

Ribavirin

300 mg to 700 mg orally twice daily.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01353911 - Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) | Biotech Hunter | Biotech Hunter